Spectrum Pharmaceuticals, Inc. (NASDAQ:SPPI) Q4 2017 Earnings Conference Call - Preliminary Transcript
Mar 06, 2018 • 04:30 pm ET
Good day, ladies and gentlemen, and welcome to the Spectrum Pharmaceuticals Fourth Quarter 2017 Financial Results Conference Call. At this time all participants are in a listen only mode. (Operator Instructions) As a reminder, this call is being recorded.
I'd now like to turn the conference over to Shiv Kapoor, Vice President of Strategic Planning and Investor Relations. Sir, you may begin.
Thanks. Good afternoon, and thank you for joining us today for Spectrum's fourth quarter 2017 financial results conference call. Our press release is available on our website at www.sppirx.com.
Joe Turgeon our CEO and President will start the call today and provide an overview. This will be followed by a financial discussion by our CFO, Kurt Gustafson, and the discussion for operation, by our COO, Tom Riga.
During this call, we will be making forward-looking statements. These statements are not guarantees of future performance and undue reliance should not be placed upon them. Such forward-looking statements necessarily involve known and unknown risks and uncertainties which may cause actual performance and financial results in future periods to differ materially from any projections of future performance or results expressed or implied, by such forward-looking statements.
With that, let me hand the call over to Joe.
Thank you, Shiv, and thanks everybody for joining us on the call today and for your -- wanting to hear about Spectrum today. This is my first call addressing you as the CEO of Spectrum. It's an honor and responsibility that I am humble to have. I thank the Board for the appointment, and I want to give shareholders the confidence that I will drive this organization forward with the focus, discipline and accountability needed to take Spectrum to the next level of growth.
In addition, let me offer perspective on how I will execute these quarterly calls moving forward. I expect this calls to be concise, transparent and focused around the key drivers of our progress. 2017 was a breakthrough year for Spectrum driven by significant advancements in our pipeline along a solid operational performance. We continue to aggressively develop Poziotinib and ROLONTIS which puts us in a position to start 2018 with strong momentum as we reach the important development milestones with both programs.
The milestones for 2018 will provide significant insight in unlocking the potential value of these assets. Key goals for 2018 include, first the aggressive development of Poziotinib for exon 20 insertion mutations. This includes rapid enrollment of our multicenter study in non-small cell lung cancer, continued collaboration with MD Anderson and working with the FDA on an optimal regulatory pathway. This year we expect to have new and updated data on response rates, duration of response and PFS in both EGFR and HER2 exon 20 insertion mutations.
In addition, we believe there are strong clinical potential of Poziotinib across solid tumors where exon 20 insertion mutations exist, this is exciting. Secondly we plan to file the BLA for ROLONTIS in Q4 of this year. We have made significant progress in